Abstract
Data from the phase II S1512 trial indicate that patients with inoperable metastatic desmoplastic melanoma are highly responsive to first-line pembrolizumab. As such, anti-PD-1 monotherapy, rather than current combinations such as nivolumab-relatlimab, should be considered for these patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
